Gastrointestinal diagnoses in patients with eating disorders: A retrospective cohort study 2010–2020
Neurogastroenterology & Motility · 2024
DOI: 10.1111/nmo.14782 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Neurogastroenterology & Motility, 2024. Verfasst von Mariana N Almeida und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Neurointestinal Health, Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Feeding and Eating Disorders, Gastrointestinal Diseases. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Background and Aims Gastrointestinal (GI) disorders are common in patients with eating disorders. However, the temporal relationship between GI and eating disorder symptoms has not been explored. We aimed to evaluate GI disorders among patients with eating disorders, their relative timing, and the relationship between GI diagnoses and eating disorder remission.
Methods
We conducted a retrospective analysis of patients with an eating disorder diagnosis who had a GI encounter from 2010 to 2020. GI diagnoses and timing of eating disorder onset were abstracted from chart review. Coders applied DSM‐5 criteria for eating disorders at the time of GI consult to determine eating disorder remission status.
Results
Of 344 patients with an eating disorder diagnosis and GI consult, the majority (255/344, 74.2%) were diagnosed with an eating disorder prior to GI consult (preexisting eating disorder). GI diagnoses categorized as functional/motility disorders were most common among the cohort (57.3%), particularly in those with preexisting eating disorders (62.5%). 113 (44.3%) patients with preexisting eating disorders were not in remission at GI consult, which was associated with being underweight (OR 0.13, 95% CI 0.04–0.46, p < 0.001) and increasing number of GI diagnoses (OR 0.47 per diagnosis, 95% CI 0.26–0.85, p = 0.01).
Conclusions
Eating disorder symptoms precede GI consult for most patients, particularly in functional/motility disorders. As almost half of eating disorder patients are not in remission at GI consult. GI providers have an important role in screening for eating disorders. Further prospective research is needed to understand the complex relationship between eating disorders and GI symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Neurointestinal Health, Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Division of Pediatric Gastroenterology, Hepatology and Nutrition, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Helen Burton-Murray, Kyle Staller
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Almeida, M. N., Atkins, M., Garcia-Fischer, I., Weeks, I. E., Silvernale, C. J., Samad, A., Rao, F., Burton-Murray, H., & Staller, K. (2024). Gastrointestinal diagnoses in patients with eating disorders: A retrospective cohort study 2010–2020. Neurogastroenterology & Motility. https://doi.org/10.1111/nmo.14782
Vancouver
Almeida MN, Atkins M, Garcia-Fischer I, Weeks IE, Silvernale CJ, Samad A, et al. Gastrointestinal diagnoses in patients with eating disorders: A retrospective cohort study 2010–2020. Neurogastroenterology & Motility. 2024. doi:10.1111/nmo.14782
BibTeX
@article{Almeida2024,
author = {Almeida, Mariana N and Atkins, Micaela and Garcia-Fischer, Isabelle and Weeks, Imani E and Silvernale, Casey J and Samad, Ahmad and Rao, Fatima and Burton-Murray, Helen and Staller, Kyle},
title = {Gastrointestinal diagnoses in patients with eating disorders: A retrospective cohort study 2010–2020},
journal = {Neurogastroenterology & Motility},
year = {2024},
doi = {10.1111/nmo.14782}
}
EUVIMED